logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

In high-risk stage II CRC, shorter oxaliplatin-based adjuvant chemotherapy gives mixed results

3 months of CAPOX and 6 months of FOLFOX are viable options.